Skip to content

Virtual Reality Based Exercise Training Versus Mulligan Mobilization on Shoulder Posture and Function in Subacromial Impingement Syndrome

Virtual Reality Based Exercise Training Versus Mulligan Mobilization on Shoulder Posture and Function in Subacromial Impingement Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07369934
Enrollment
74
Registered
2026-01-27
Start date
2025-12-13
Completion date
2026-05-01
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subacromial Impingement Syndrome

Keywords

subacromial impingement syndrome, Virtual reality, Mulligan mobilization, shoulder function, shoulder posture

Brief summary

The study will compare the effect of virtual reality based exercise training versus Mulligan mobilization in addition to exercise therapy added to both groups on shoulder posture and function in subacromial impingement syndrome.

Interventions

OTHERVirtual Reality

Fully immersive virtual reality mounted headset will be used

OTHERMulligan mobilization

posterolateral shoulder Mulligan mobilization with movement (MWM) will be used

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Patients will be referred from the orthopedic surgeon with a diagnosis of stage II SIS with the following criteria: 1. Participants ranged in age from 30-50 years old. 2. Participants are from non-athletes from the general population. 3. Unilateral shoulder pain that is localized either anteriorly or laterally to the acromion. Pain that occurs or worsens when the affected shoulder is in flexion and/or abduction. 4. Four of the following should be present in the included patients: Neer impingement test, Hawkins' test, Pain was replicated in the supraspinatus empty-can test, a painful arc of movement from 70° to 120°, and painful greater tuberosity of the humerus. 5. BMI range 18.5- 29.9 Kg/m².

Exclusion criteria

* 1\) Patients who, during the previous three months, underwent shoulder physical treatment and/or an acute pain flare. 2\) Patients who have undergone surgeries for tendon repair. 3) Malignancy, epilepsy, pregnant women, and/or systemic conditions like chronic renal or liver failure. 4\) Mini-Mental State Examination test (MMSE) (\< 24/30) to exclude cognitive impairment and/or significant vision impairment (if they couldn't read the introduction while wearing the Head Mounted Device (HMD). 5\) Corticosteroid injection during the last three months or used steroids chronically. 6\) Adhesive capsulitis, glenohumeral joint instability, Numbness or tingling of the upper limb, and/or full-thickness tear of the rotator cuff.

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity during shoulder elevationpain intensity at the start of session 1 to the end of 1 month of treatmentIt will be measured using the Numerical Pain Rating Scale (NPRS)
Shoulder functionshoulder function at the start of session 1 to the end of 1 month of treatmentThe Shoulder Pain and Disability Index (SPADI) will be used to measure the shoulder function.
Shoulder flexion range of motionshoulder flexion at the start of session 1 to the end of 1 month of treatmentThe Clinometer Application will be used to measure it.
Shoulder abduction range of motionshoulder abduction at the start of session 1 to the end of 1 month of treatmentThe Clinometer Application will be used to measure it.
shoulder postureshoulder posture at the start of session 1 to the end of 1 month of treatmentSagittal Shoulder Angle will be used to measure the shoulder posture

Secondary

MeasureTime frameDescription
Patients' enjoymentIt will be evaluated at the end of the last session (after 1 month)A 7-point likert scale will be used to the evaluate the level of the patients' enjoyment at the end of the last session.
patients' adherence to treatment sessionspatients' adherence at the start of session 1 to the end of 1 month of treatmentpatients' numbers of attended sessions will be calculated at the end of 1 month of treatment.

Countries

Egypt

Contacts

CONTACTSara M Meselhy, Demonstrator
sara.mohsen@cu.edu.eg+01222518092
CONTACTAfaf M Tahoon, lecturer
Afaf_tahoon@cu.edu.eg+01015401783
STUDY_CHAIREnas Fawzy Youssed, Professor Doctor

Cairo University

STUDY_DIRECTORAfaf M Tahoon, lecturer

Cairo University

STUDY_DIRECTORMohamed A Kotb, Assistant professor

Cairo University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026